The QualityStocks Daily Wednesday, August 26th, 2020

Today's Top 3 Investment Newsletters

Schaeffer's (NAK) +44.70%

QualityStocks (MMTIF) +41.03%

StreetInsider (BIGC) +33.54%

The QualityStocks Daily Stock List

Artificial Intelligence Technology Solutions, Inc. (AITX)

OTC Markets, Emerging Growth, MarketWatch, Street Insider, Macroaxis, Stockhouse, Barchart, YCharts, Finbox, OTC.Watch, Simply Wall St, Morningstar, Investors Hangout, Business Wire, Market Screener, Dividend Investor, Fintel, CSI Market, last10k, GlobeNewswire, OTC Dynamics, Nasdaq, Dividend.com, Seeking Alpha, Investing.com, Baystreet.ca, Stockopedia, Wallet Investor, GuruFocus, TradingView, and InvestorsHub reported earlier on Artificial Intelligence Technology Solutions, Inc. (AITX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Artificial Intelligence Technology Solutions, Inc. concentrates on the delivery of artificial intelligence (AI) and robotic solutions for operational, security, as well as monitoring needs. The Company has its wholly-owned subsidiary Robotic Assistance Devices (RAD). The Company was previously known as On The Move Systems Corp. It changed its name to Artificial Intelligence Technology Solutions, Inc. in August of 2018.

Incorporated in 2010, Artificial Intelligence Technology Solutions has its headquarters in Henderson, Nevada. The Company also has assembly and sales offices in California, Florida, and Canada. Artificial Intelligence Technology Solutions lists on the OTC Markets.

Robotic Assistance Devices’ mission is to deliver AI-based solutions that enable organizations to solve complex challenges. This is while delivering immediate return on investment (ROI). RAD technology improves the simplicity and economics of patrolling and guard services; it enables experienced personnel to concentrate on more strategic tasks. Therefore, customers augment the capabilities of existing staffs and gain higher levels of situational awareness. They accomplish this all at considerably reduced cost.

In early August, Artificial Intelligence Technology Solutions announced that its wholly-owned subsidiary, Robotic Assistance Devices (RAD), received an opening order and entered into an agreement to develop custom solutions for Grapefruit USA, Inc. (OTCQB:GPFT). As part of this agreement, Grapefruit USA will be optimizing its existing and future security with RAD’s solutions, starting with an order for two ROSA units to be delivered within ninety days.

ROSA (Responsive Observation Security Agent) is an autonomous response device. It is the first and only completely self-contained security and communication device in the market. ROSA provides a 180° field of view from the device so one can see more of their site. ROSA delivers a premier security experience by way of RAD’s in-house developed software suite. This includes RADSOC and RADSight.

Moreover, Artificial Intelligence Technology Solutions announced that Robotic Assistance Devices (RAD) received an order for three ROSA units to be deployed in the greater Los Angeles, California area. The units will be deployed at a high-end national grocery store and also at two Class A commercial properties.

Last week, Artificial Intelligence Technology Solutions announced that Robotic Assistance Devices (RAD) is working to complete two provisional patent filings. They may result in up to eight utility patents when RAD completes the required filings, and those filings are accepted by the United States Patent and Trademark Office (USPTO). The provisional patents are related to solutions under development that have not been publicized as of this date (August 19, 2020).

Artificial Intelligence Technology Solutions, Inc. (AITX), closed Wednesday's trading session at $0.0047, up 9.3023%, on 9,114,657 volume with 261 trades. The average volume for the last 3 months is 20,611,745 and the stock's 52-week low/high is $0.004/$4.00.

Aspira Women's Health, Inc. (AWH)

Stocklight, Stock Analysis, Market Chameleon, Invest Million, ChartMill, The Fly, TMXmoney, TipRanks, Nasdaq, Webull, Stockopedia, Investcom.com, Market Screener, Preferred Stock Channel, Morningstar, Stockhouse, MarketWatch, InvestorsHub, Seeking Alpha, Business Insider, GlobeNewswire, DBT News, Investors Observer, Invest Chronicle, OTC Markets, ETF.com, and Simply Wall St reported beforehand on Aspira Women's Health, Inc. (AWH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aspira Women's Health, Inc. is a bio-analytical based women’s health company centered on gynecologic disease. It is transforming women’s health with the discovery, development, and commercialization of unique testing options and bio-analytical solutions. These help physicians assess risk, optimize patient management, as well as improve gynecologic health outcomes for women.

The Company previously went by the name Vermillion, Inc. It changed its corporate name to Aspira Women's Health, Inc. in June of this year. Established in 1993, the Company is based in Austin, Texas. Aspira Women's Health lists on the NasdaqCM.

OVA1®plus combines Aspira Women’s Health’s FDA (Food and Drug Administration)-cleared products OVA1® and OVERA® to detect risk of ovarian malignancy in women with adnexal masses. ASPiRA GenetiX(SM) testing offers targeted and comprehensive genetic testing options with a gynecologic emphasis.

Aspira has greater than a decade of expertise in ovarian cancer risk assessment. The Company has expertise in pioneering research to inform its next generation of products. Aspira’s concentration is on delivering products that permit healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans.

OVA1® and OVERA® are blood tests with consummate abilities to detect ovarian cancer risk in women diagnosed with a pelvic mass. For women with an adnexal mass, OVA1®plus is a reflex process that first performs OVA1 and then performs OVERA if the OVA1 result is in the intermediate range.

Aspira Genetix is genetic testing for hereditary breast and ovarian cancer. Aspira Labs® offers complete and targeted genetic testing options for Hereditary Breast and Ovarian cancer, and also Carrier Screening to help guide medical management for patients. Aspira GenetiXSM provides complete coverage of each gene through full gene sequencing, a specialized genetic testing method to detect different kinds of mutations by using one technology, increasing the accuracy of results.

This month, Aspira Women’s Health reported its financial results for Q2 ended June 30, 2020. Revenue on a per test performed basis for OVA1 Revenue was $295 in Q2 of 2020 versus $324 in Q1 of 2020. Gross Profit on OVA1 Product Revenue was $268,000 (a 37 percent Profit Margin) for Q2 of 2020 versus $491,000 for the same period in 2019 (a 45 percent Profit Margin).

The Cash balance at June 30, 2020 was $10.9 million, and Cash Utilization in Q2 of 2020 was $3.3M, offset by Cash received for the exercise of warrants of $5.1M and the receipt of the $1.0 million PPP loan. Cash Utilization was lower than the prior quarter chiefly because of less expenses incurred as a result of COVID.

Aspira Women's Health, Inc. (AWH), closed Wednesday's trading session at $2.94, off by 3.9216%, on 596,804 volume with 4,055 trades. The average volume for the last 3 months is 1,098,993 and the stock's 52-week low/high is $0.350600004/$5.7800002.

Conversion Labs, Inc. (CVLB)

MarketWatch, Stock Day Media, Zacks, Nasdaq, InvestorsHub, Market Screener, GuruFocus, Stockopedia, last10k, Equity Clock, Morningstar, MarketBeat, Seeking Alpha, OTC Markets, TMXmoney, MacroTrends, Simply Wall St, PR Newswire, Investing.com, Barchart, Wallet Investor, Proactive Investors, docoh, YCharts, Finbox, Stockhouse, Digital Journal, and GlobeNewswire reported previously on Conversion Labs, Inc. (CVLB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Conversion Labs, Inc. is a direct-to-consumer telemedicine and wellness company. It has a portfolio of online direct-to-consumer brands. Its PDFSimpli subsidiary is a Software-as-a-Service (SaaS) that permits users to convert, edit, sign, and share PDF documents online. The Company previously went by the name Immudyne, Inc. It changed its name to Conversion Labs, Inc. in June of 2018. Incorporated in 1987, Conversion Labs has its head office in New York City.

Conversion Labs’ brands combine virtual medical treatment with prescription medications and innovative Over-the-Counter (OTC) products. The Company’s network of licensed physicians offers telemedicine services and direct-to-consumer pharmacy to consumers throughout the United States.

Regarding its focus on changing healthcare, Conversion Labs is applying its direct response marketing expertise to healthcare. It is concentrating on providing a convenient, cost-effective, and smarter way for consumers to access high quality OTC products and prescription medications.

The Company’s brands include Shapiro MD. This brand features personalized treatment plans for male and female hair loss. Another brand is iNR Wellness MD - a "super-food" for immune system support. Moreover, the Rex MD brand is E.D. (erectile dysfunction) meds prescribed and shipped discreetly to the consumer. In addition, the SOS RX brand is prescription medications for disaster scenarios.

Last week, Conversion Labs reported results for Q2 and first half ended June 30, 2020. Revenue in Q2 totaled a record $9.1 million, up 237 percent. For the first half of 2020, Revenue grew 148 percent to a record $13.4 million.

Gross Margin totaled $6.9 million, up 238 percent. In the first half of 2020, Gross Margin grew 132 percent to $9.4 million. For Q2 2020, Customers on Subscription across all brands almost doubled over the prior quarter. Investments in customer acquisition for Rex MD drove robust growth in Subscription Revenue.

Conversion Labs advanced the development of its new cloud based telemedicine platform, Veritas MD, in Q2 2020. Veritas MD builds upon the Company’s existing digital marketing platform.

Moreover, Conversion Labs completed development for a number of new Shapiro MD prescription treatments and OTC products for male and female hair loss. This includes proprietary compounded formulations. Also, the Company appointed award-winning physician, Dr. Jeremy Fine, and foremost health and wellness doctor, Dr. Jeff Toll, to Conversion Labs’ Medical Advisory Board.

Conversion Labs has been invited to present at the LD Micro 500 Virtual Institutional Investor Conference being held on September 1-4, 2020. The Chief Executive Officer of Conversion Labs, Mr. Justin Schreiber, is scheduled to present on Tuesday, September 1, at 9:40 a.m. Eastern Time. Mr. Schreiber will be joined by Conversion Labs’ Chief Financial Officer, Mr. Juan M. Piñeiro Dagnery, for the presentation and virtual one-on-one meetings with institutional analysts and investors.

Conversion Labs, Inc. (CVLB), closed Wednesday's trading session at $1.12, up 10.8911%, on 433,584 volume with 340 trades. The average volume for the last 3 months is 659,436 and the stock's 52-week low/high is $0.100000001/$2.1400001.

Eyenovia, Inc. (EYEN)

NetworkNewsWire, Stocktwits, BioPharmCatalyst, 4-Traders, Zacks, Market Chameleon, Nasdaq, FinScreener, Insider Monitor, Stockhouse, Trade Ideas, GlobeNewswire, MacroTrends, TipRanks, InvestorsHub, Morningstar, Street Insider, Simply Wall St, Investing.com, Seeking Alpha, ETF.com, Equities.com, Stocknews, Invest Chronicle, and GuruFocus reported beforehand on Eyenovia, Inc. (EYEN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company listed on the NasdaqCM. It is developing a pipeline of Microdose Array Print (MAP™) therapeutics utilizing its patented piezo-print delivery technology. With its microdosing technology, Eyenovia is developing a treatment for progressive myopia, a condition associated with several back of the eye diseases and may result in visual disability. The Company formerly went by the name PGP Holdings V, Inc. It changed its corporate name to Eyenovia, Inc. in May of 2014. The Company is based in New York City.

Eyenovia is working to achieve clinical microdosing of next-generation formulations of well-established ophthalmic pharmaceutical agents employing its high-precision targeted ocular delivery system. The system has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments.

Currently, Eyenovia’s pipeline is focused on the late-stage development of microdosed medications for presbyopia, the aforementioned myopia progression, and mydriasis. Concerning the Company’s technology, with the Optejet® dispenser, medications become more effective as self-administration is simpler and more reliable. Furthermore, products delivered in the Optejet® are safe because of lower amounts of drug entering the blood stream with fewer side effects on the eyes. The smart technology accompanying the Optejet® helps patients manage their therapy with reminders and therapy adherence measures.

At the end of June, Eyenovia announced that it resumed patient enrollment for its Phase III CHAPERONE study for the treatment of progressive myopia, following a temporary pause because of the COVID-19 pandemic. The CHAPERONE study is a U.S.-based, multi-center, randomized, double-masked trial that will enroll greater than 400 children between 3-12 years of age. The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia utilizing Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.

This month, Eyenovia and Arctic Vision announced that they entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and South Korea. Arctic Vision is a clinical stage biotechnology enterprise centered on developing and commercializing unique ophthalmology therapies in China and Asia.

With this agreement, Eyenovia may receive up to a total of $45.75 million in upfront payments and additional payments, based on different development and regulatory milestones. These include the initiation of clinical research and approvals in Greater China and South Korea, and development costs.

For Q2 of 2020, Eyenovia’s Net Loss was roughly $5.0 million, or $(0.25) per share, versus a Net Loss of roughly $5.3 million, or $(0.44) per share for Q2 of 2019. As of June 30, 2020, Eyenovia’s Cash Balance was roughly $10.2 million.

Eyenovia, Inc. (EYEN), closed Wednesday's trading session at $3.64, off by 1.6216%, on 279,051 volume with 1,372 trades. The average volume for the last 3 months is 1,168,175 and the stock's 52-week low/high is $1.11000001/$6.92000007.

Flower One Holdings, Inc. (FLOOF)

NetworkNewsWire, Pot Network, Midas Letter, Invest Tribune, Investor Ideas, Investor Place, NIC Investors, Dividend Investor, Stockwatch, Investors Hangout, Cannabis Life News, Stockhouse, GlobeNewswire, OTC Markets, Investing News, New Cannabis Ventures, Cash Crop Today, Pot Stock News, MarketBeat, Street Insider, TradingView, Business Insider, InvestorsHub, Green Market Report, Nasdaq, and Morningstar reported previously on Flower One Holdings, Inc. (FLOOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is on the fast track to becoming the leading cannabis cultivator, producer, and innovator in the State of Nevada. The Company owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms. Furthermore, its owns the established NLV Organics consumer brand of cannabis products. OTCQX-listed, Flower One Holdings is based in Toronto, Ontario.

The Company is converting its 455,000 square-foot greenhouse and production facility for cultivating and processing high-quality cannabis at scale. The facility is the largest in the State of Nevada. Combined, the flagship greenhouse facility and production facility (upon being totally operational) and the North Las Vegas facility provide Flower One Holdings with 480,000 square feet of capacity for cultivation and processing, production and high-volume packaging of dry flower, cannabis oils, concentrates, and infused products.

Flower One is completely licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in Nevada. Currently, the Company holds licensing agreements with its Brand Partners - Flyte Concentrates, Rapid-Dose Therapeutics' Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, Grenco Science (G Pen), and The Medicine Cabinet.

This past June, Flower One Holdings announced its latest partnership agreement with Lift Ticket Laboratories. Via this partnership, Flower One will become the exclusive brand production partner for the Lift Tickets brand in Nevada, bringing all of Lift Tickets Laboratories' award-winning pre-roll products to Nevada. In addition, Lift Tickets Laboratories will be implementing numerous industry-leading proprietary pre-roll production methods and techniques at Flower One's flagship greenhouse facility to further enhance the Company's pre-roll manufacturing capabilities.

Earlier this month, Flower One announced preliminary July Gross Sales of $3.2 million. This represents a 64 percent sequential increase over June 2020. It is an indication that Flower One's market presence is rebounding strongly post the partial reopening of Nevada hotels and casinos on June 4, 2020.

Last week, Flower One announced the appointment of Ms. Salpy Boyajian to its Board of Directors. Ms. Boyajian officially joined Flower One Holdings in October of 2018 following the acquisition of NLV Organics, which she co-founded in 2014. At present, she serves as Flower One's Chief Operating Officer, Nevada Operations, and was one of the original winning applicants granted cannabis licenses by the State of Nevada.

Flower One Holdings, Inc. (FLOOF), closed Wednesday's trading session at $0.31, up 1.0595%, on 43,261 volume with 41 trades. The average volume for the last 3 months is 131,201 and the stock's 52-week low/high is $0.248799994/$1.68990004.

GBT Technologies, Inc. (GTCH)

Zacks, Stock Day Media, TipRanks, VentureLine, OTC Dynamics, Real Investment Advice, Dividend Investor, Stockhouse, Nasdaq, GuruFocus, Wallet Investor, OTC.Watch, Investing.com, Investors Hangout, Stockwatch, FX Empire, Financial Buzz, docoh, InvestorsHub, Street Insider, Market Screener, Investor Ideas, GlobeNewswire, Morningstar, Simply Wall St, Super Stock Screener, and Whale Wisdom reported previously on GBT Technologies, Inc. (GTCH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

GBT Technologies, Inc. specializes in the development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies. A development-stage enterprise, it has a portfolio of Intellectual Property (IP) that, upon commercialization, will include smart microchips, mobile and security applications and protocols, and supporting cloud software. The Company formerly went by the name Gopher Protocol, Inc. It changed its name to GBT Technologies, Inc. in August of 2019. Founded in 2009, GBT Technologies lists on the OTC Markets.

GBT’s system foresees the creation of a worldwide mesh network. The heart of this system will be its advanced microchip technology that can be installed in any mobile or fixed device globally. The Company envisions this system as a low-cost, secure, private mesh network between any enabled devices, providing shared processing, advanced mobile database management/sharing, and enhanced mobile features as an alternative to traditional carrier services.

GBT Technologies has its GopherInsight™ wireless mesh network technology platform and its Avant! AI, for mobile and fixed solutions. GBTs Core Technology is a unique platform with products that will change the way people interact with technology and each other.

The Company’s Platform Technology is called the aforementioned GopherInsight™. It uses “public” RF spectrum to facilitate a private network between enabled devices. Products that use GopherInsight™ can have network access without using traditional Bluetooth, Cellular, or Satellite connectivity.

This month, GBT Technologies announced that its Joint Venture (JV), GBT Tokenize Corp. (GBT/Tokenize), completed Phase I of qTerm, a human vitals device, powered by AI, which is the device size and physical dimensions. The qTerm device is targeted to measure body temperature, blood pressure, and heart rate – all with a simple touch of the finger.

GBT Technologies’ belief is that the miniaturization of the device is an important factor to its success. However, advanced circuitry and sensory systems have to fit on board. The Company simulated and evaluated sizes and shapes of qTerm and concluded a user friendly, efficient sizes, and shape for version one.

On April 19, 2020, GBT/Tokenize filed a provisional patent with the United States Patent and Trademark Office (USPTO) for proximity circle. The application has been assigned serial number 63012205. The system includes an AI engine that enables “Safety Circle” per users. The system records users body temperature and GBT Technologies believes it can be used to build a HOT ZONES database.

GBT Technologies, Inc. (GTCH), closed Wednesday's trading session at $0.01325, up 5.1587%, on 605,613 volume with 48 trades. The average volume for the last 3 months is 1,050,055 and the stock's 52-week low/high is $0.0087/$4.4499998.

Greene Concepts, Inc. (INKW)

Stock Reads, Pink Investing, All Cap Research, OTC PR Wire, InvestorsHub, Guerilla Stock Trading, Investors Hangout, Dividend Investor, Stockwatch, OTC Markets, OTC Dynamics, Street Insider, Market Screener, Investor Ideas, FX Empire, Financial Buzz, Stockhouse, Stockopedia, Ceo.ca, Seeking Alpha, Newsfilecorp, WeTradeHQ, TradingView, Nasdaq, GlobeNewswire, EIN Presswire, Business Insider, Morningstar, and Wallet Investor reported earlier on Greene Concepts, Inc. (INKW), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Greene Concepts, Inc. is an emerging leader in the global scientifically formulated beverage industry. Through its earlier acquired wholly-owned subsidiary, Mammoth Ventures, Inc., the Company has entered into the specialty beverage and bottling business. Greene Concepts has completed the 100 percent acquisition of Mammoth Ventures. Greene Concepts is based in Clovis, California and lists on the OTC Markets.

Mammoth Ventures is a holding company that includes the 60,000 sq. ft. beverage and bottling facility located just outside of Asheville, North Carolina. Furthermore, the acquisition of the holding company includes the building, all bottling equipment, fixtures, inventory, and any and all other assets held and owned by Mammoth Ventures, Inc.

The facility will concentrate on an array of beverage product lines. These include, but are not limited to, CBD (cannabidiol) infused beverages, spring and artesian water, and enhanced athletic drinks in addition to other product offerings. Also, through its subsidiary, Water Club, Inc., it intends to pursue subscription-based delivery of water and scientifically formulated beverages directly to the consumers home, and market the convenience of this service by way of social media affiliate marketing partners.

Greene Concepts has a new marketing and distribution focus in the lucrative Southeast Asia bottled water market. Along with domestic market growth, It plans for expansion into the fast growing Southeast Asia market. This includes Singapore, Indonesia, Thailand, Malaysia, and Vietnam.

Greene Concepts has signed a property purchase agreement for an additional 10 acres of land adjacent to its Marion, North Carolina bottling facility. This additional acreage will provide the Company with the ownership of seven wells and unlimited access to the underground pristine water aquifer that lays deep beneath the property located within the Pisgah National forest.

Recently, Greene Concepts celebrated the grand opening of the Santa Rosa Band of Cahuilla Indians' Pit Stop gas station and convenience store situated in Mountain Center, California. Greene Concepts recently signed a purchase order agreement with the Santa Rosa Pit Stop and is presently selling its' BE WATER™ brand at that location. The Santa Rosa Pit Stop, LLC gas station and convenience store is owned and operated by the Santa Rosa Band of Cahuilla Indians.

In late July, Greene Concepts reported that it completed a distribution and purchase agreement with a U.S. military Veteran distributor located in Louisiana, Mr. Derek Nothnagel. Mr. Nothnagel focuses on the product distribution of BE WATER™ utilizing his unique process called 'linchpin logistics'. A former U.S. Marine Veteran, Mr. Nothnagel is the first U.S. Veteran to sign as a distributor within the new Greene Concepts Be Water Distributorship Program. The program aims to provide economic opportunities for Veterans via the distribution of BE WATER™ across the country.

This month, Greene Concepts announced that its' BE WATER™ artesian spring water brand Distributorship Initiative has been set up. It is currently rolling out in five States: California, Florida, Georgia, Louisiana, and Oregon. Each of these States are set to increase the number of retail convenience stores and chain stores carrying BE WATER™.

Greene Concepts, Inc. (INKW), closed Wednesday's trading session at $0.0014, off by 6.6667%, on 8,190,712 volume with 65 trades. The average volume for the last 3 months is 27,897,140 and the stock's 52-week low/high is $0.001/$0.0103.

MJardin Group, Inc. (MJARF)

Street Register, CannabisMarketCap, Trading View, NIC Investors, OTC Markets, New Cannabis Ventures, Stockhouse, GuruFocus, Midas Letter, Stockwatch, and MarketBeat reported beforehand on MJardin Group, Inc. (MJARF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

OTCQX-listed, MJardin Group, Inc. is a leader in premium cannabis production. The Company is a cannabis management platform with comprehensive experience in cultivation, processing, distribution and retail. MJardin has more than 10 years of commercial growing experience in North America. Established in 2014, MJardin Group is headquartered in Denver, Colorado. The Company also has an office in Toronto, Ontario.

At present, MJardin Group owns, manages or advises on a portfolio of 32 cannabis operations. The Company has refined cultivation methodologies, developed state-of-the-art facilities and implemented vertical integration for and on behalf of license owners. It has designed 105 cannabis facilities across 13 U.S. States, 3 Canadian Provinces and Australia. Since 2014, it has produced 110,000 kilograms of cannabis.

MJardin has entered into a definitive agreement to acquire Carson City Agency Solutions, dba Cannabella, an operator of an extraction facility and producer of edibles and topicals in Carson City, Nevada. This Transaction will add extraction capabilities to MJardin’s present cultivation operations in Nevada, allowing it to use a portion of its cultivation output for extracts towards edibles, topicals and other potential product lines.

MJardin Group has completed construction of “GRO”. This an indoor cannabis cultivation facility situated in Dunnville, Ontario. The Company has submitted its Evidence of Readiness package to Health Canada. The facility is a joint-venture (JV) between MJardin Group (75 percent) and Grand River Organics (25 percent).

The estimation is that the 11,000 square foot facility will produce 1,260 kg of premium flower and 454 kg of trim, for a total of 1,714 kg of product annually. “GRO” is MJardin Group’s third Canadian cannabis cultivation facility to complete construction and second in Ontario as it joins “WILL”, a 32,800 square foot cultivation facility in Brampton that was awarded its sales license in December of 2018.

MJardin Group also has its Warman Road project in Winnipeg, Manitoba. This is a hybrid facility encompassing indoor and greenhouse production along with full EU GMP certified extraction, processing and packaging capabilities.

MJardin Group previously announced that it agreed to issue 741,765 common shares in the capital of MJardin to the seller of Carson City Agency Solutions LLC (which does business under the trade name Cannabella), as a non-refundable pre-payment of the $4.5 million USD purchase price, of which $500,000 USD was paid as cash consideration at the time of execution for the earlier announced acquisition of Cannabella. Cannabella’s products are already in roughly 50 of the 68 retail dispensaries in Nevada.

Recently, MJardin Group announced that it entered into a partnership with Robes, Inc., a luxury cannabis brand house focused on bringing exotic and rare strains to Canadian consumers. With this partnership agreement, MJardin will cultivate specific innovative strains as selected by Robes, for the Canadian market. Robes owns brands such as BLLRDR and Robes Cannabis. Robes also has an extensive catalogue of market-leading cannabis genetics including the Afghani Bullrider.

MJardin Group, Inc. (MJARF), closed Wednesday's trading session at $0.0398, up 42.1429%, on 128,800 volume with 34 trades. The average volume for the last 3 months is 59,395 and the stock's 52-week low/high is $0.028/$0.940800011.

Humble Energy, Inc. (HUML)

Hot Stocked, Penny Stock Hub, Penny Stock Base, OTC Markets, Market Wire News, TipRanks, Investors Observer, Advanced Equity Research, TradingCompare, Investors Hangout, Wallet Investor, Market Screener, Stockopedia, Simply Wall St, MarketWatch, InvestorsHub, Dividend Investor, and Morningstar reported earlier on Humble Energy, Inc. (HUML), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Humble Energy, Inc. is an oil and gas production and exploration company listed on the OTC Markets. Natural gas is 85 percent of the Company’s production. Humble Energy also owns coal minerals. It owns coal minerals in fee simple title that are high BTU metallurgical quality coal. Additionally, Humble has Coking coal with a high Button nine plus that blends with lesser coals to make steel. Humble Energy has its head office in Paron, Arkansas.

It commenced operations as a private Texas Corporation in 1999 as Humble Petroleum, Inc. In May 2009, Humble Petroleum, Inc. bought Humble Energy, Inc. transferring ownership interests in 83 wells in Texas, Wyoming, New Mexico, Kansas and Oklahoma. The wells purchased 85 percent of the common stock in Humble Energy, Inc. On December 30, 2013, Humble Petroleum, Inc. transferred the remaining assets of Humble Petroleum, Inc. that included oil and natural gas wells, coal, ATTI, and Power Klean. Humble Petroleum, Inc. common shares became Humble Energy, Inc. shares.

Currently, Humble Energy is participating in drilling 10 wells in the prolific Cotton Valley sand formation in Louisiana. The first 9 horizontal wells came in at 108,000,000 cubic feet per day on a 44/64 choke. Because of the successful results of the first 9 wells Humble has agreed to participate in the drilling of 4 more Cotton Valley formation wells.

Furthermore, the Company is participating in the drilling of 7 more wells in the Haynesville shale formation. Twenty more total wells will be drilled. Moreover, Humble has participated in drilling and completing producing horizontal wells in Kingfisher County, Oklahoma. The Company states that production to date has been excellent.

Humble Energy has its Power Klean product. Power Klean cleanses out contaminated motor oil. Tests show that the system removes greater than 85 percent of the harmful contaminates, wear metals, and carbon that typical oil changes miss. Features of Power Clean include lessening friction; extending engine life; increasing horsepower, and improving gas mileage. In addition, features include keeping oil cleaner for higher performance oil changes.

Humble Energy, Inc. (HUML), closed Wednesday's trading session at $0.43, up 152.9412%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 233 and the stock's 52-week low/high is $0.119999997/$3.71000003.

Alternate Health Corp. (AHGIF)

Wallet Investor, Weed Newswire, GuruFocus, CannabisFN, OTC Markets, Marijuana Index, Stockhouse, MicroCapFinder, OTC Insider, MarketWatch, InvestorsHub, The Street, Daily Marijuana Observer, Investing News, Trading View, Cannabis Life Network, and Market Screener reported earlier on Alternate Health Corp. (AHGIF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Alternate Health Corp. is a global cannabis company listed on the OTC Markets’ OTCQB. It provides software solutions for the medical cannabis industry. The Company utilizes best in class technology, research, education, production, and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. Alternate Health has its headquarters in Toronto, Ontario. The Company has additional offices in Venice and Humboldt County, California and San Antonio, Texas.

Alternate Health is a diversified healthcare investment and Holdings Company. It operates via a network of subsidiaries that share proprietary, highly secure cloud-based software solutions to increase efficiencies and protect patient data. Its companies are: Alternate Health Clinics; Alternate Health Labs; Alternate Medical Media; Alternate RX; CanaPass, Inc.; and VIP-Patient.

Alternate Health develops software applications and processing systems for the medical industry employing proprietary technology platforms (VIP-Patient & CanaPass systems) to assist doctors in their practice management and patients with their need for first-rate medical care. Alternate Health’s services include practice management and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the developing medical cannabis industry.

The Company has transformed the CanaPass Patient Management system to a total Ethereum-based blockchain Electronic Medical Records (EMR)/Electronic Health Records (HER) system. Alternate Health has taken a leadership position in blockchain financial and healthcare solutions. CanaPass, Inc. provides turnkey compliance management software to doctors and Licensed Providers of medical cannabis and other controlled substances.

A key product is its Zi App Blockchain Payment Gateway. The design of it was originally to enable digital payments in cannabis. However, the system has earned considerable interest as a payment solution for even larger markets. This includes multi-level marketing, commercial leases, as well as equipment rentals.

Recently, Alternate Health announced that Mr. Kyle Kemper was appointed to the Company's Board of Directors. Mr. Kemper is the author of "The Unified Wallet: Unlocking the Digital Golden Age", which is a definitive work on the implications of blockchain technology in the modern world. He is a strong advocate for the expansion of blockchain and Bitcoin.

Mr. Howard Mann, Chief Executive Officer of Alternate Health, said, "We are thrilled to welcome Mr. Kemper to Alternate Health's Board of Directors. His deep technical knowledge, vision for what's possible and network of industry contacts are valuable assets to the Company as we take the lead in both blockchain technology and cannabis."

Alternate Health Corp. (AHGIF), closed Wednesday's trading session at $0.045, up 50.00%, on 1,995 volume with 3 trades. The average volume for the last 3 months is 8,852 and the stock's 52-week low/high is $0.019999999/$0.319999992.

Medifocus, Inc. (MDFZF)

MoneyHub, OTC Markets, Wallet Investor, SmallCapVoice, Investor Place, Investor Network, Barchart, Street Insider, Financial Content, Trading View, MarketWatch, and otc.Watch reported beforehand on Medifocus, Inc. (MDFZF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Medifocus, Inc. has a portfolio of medical technologies that use patented  Focal Thermal Technology  to treat conditions ranging from Prostate Diseases to Breast Cancer. The Company’s portfolio of medical products includes thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer. OTCQB-listed, Medifocus is based in Columbia, Maryland.

The Company owns two technology platforms with approximately 100 issued and pending U.S. and worldwide patents. One platform is the “Endo-thermotherapy Platform”. The other platform is the “Adaptive Phased Array Microwave Focusing Platform”.

Based on these proprietary technology platforms, Medifocus has developed two advanced therapeutic products. One is the Prolieve® system for the treatment of BPH. The other is the Adaptive Phased Array (APA)-1000 system for the treatment of breast cancer.

The Prolieve® Thermodilatation™ System provides symptomatic relief to men with Benign Prostatic Hyperplasia (BPH) via a simple, 45-minute, in-office treatment. Prolieve® is Food and Drug Administration (FDA) and Medicare approved for treating symptomatic BPH with more than 100,000 cases performed in the U.S. alone, and with proven long-term safety, efficacy, and durability. The purpose of the Prolieve system is to provide a relatively painless and effective alternative to drug therapy, and also certain types of surgical procedures to treat the symptoms of BPH.

Medifocus’ Heat Activated Gene Therapy, exclusively licensed from Duke University, aims at using the Company’s Focal Thermal Technology to enhance selective expression of therapeutic genes injected intratumorally to optimize cancer cell killing while lessening systemic side effects.

The APA 1000 Breast Cancer Treatment System developed by the Massachusetts Institute of Technology (MIT) has been shown in Phase 2 clinical trials to offer substantial additional shrinkage of the sizes of breast cancer in combined ChemoThermal therapy versus Chemotherapy alone. Additionally, it was shown to be effective in reducing margin positivity when patients were treated with APA 1000 before lumpectomy.

Recently, Medifocus announced that its Prolieve® Thermodilatation™ procedure for the treatment of BPH have been performed and reimbursed by insurance carriers in Hong Kong.

Dr. William Jow, said, “We are pleased that our efforts, together with the contribution from our Asian partners, are starting to yield tangible financial results from Prolieve® sales. Through our resolution in promoting Prolieve® in Asia and after having presented at three major international conferences within the past 16 months, I would like to see Prolieve® sales start to pick up in the near future both domestically and internationally. We are pleased to enter the fast-growing Asia markets where BPH and cancers of the prostate and breast are quickly becoming major public health concerns.”

Medifocus, Inc. (MDFZF), closed Wednesday's trading session at $0.0094, up 91.8367%, on 1,501 volume with 2 trades. The average volume for the last 3 months is 2,736 and the stock's 52-week low/high is $0.001099999/$0.0174.

Micromem Technologies, Inc. (MMTIF)

MarketWatch, Penny Stock Tweets, Infront Analytics, Equity Clock, InvestorsHub, SmallCapVoice, Dividend Investor, last10k, Xtremepicks, OurHotStockPicks, GuruFocus, Wallet Investor, Stockhouse, Morningstar, Stock Stars, Trading View, PennyStocks24, Capital Cube, Investors Hangout, and Pink Investing reported earlier on Micromem Technologies, Inc. (MMTIF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Micromem Technologies, Inc. is a leader in viable Sensor Technology and MRAM (Magnetoresistive Random Access Memory). At present, the Company is focused on magnetic sensor applications via its wholly-owned subsidiary, Micromem Applied Sensor Technologies, Inc. (MAST, Inc.). OTCQB-listed, Micromem Technologies is based in Toronto, Ontario. The MAST, Inc. subsidiary is based in New York, New York.

Micromem’s technologies and solutions include surface functionalization of magnetic nanoparticles; nanoparticle detection platforms to sub-ppb detection levels; customized integration of NEMS/MEMS sensor platforms; magnetic sensor solutions; and sensor-based analytical solution platforms. Technologies and solutions also include structural integrity sensors; wireless suib-surface power solutions; asset protection sensor platforms; and energy storage solutions.

Micromem Technologies designs, develops and provides sensors specific to industry needs. The MAST subsidiary centers on developing and marketing the delivery of inventive magnetic sensor applications in industries including Defense, Life Sciences, Automotive, Consumer, and Mining. MAST develops MEMS/NEMS solutions through combining disparate sensor modalities to create solutions for clients’ problems.

MAST works closely with its clients during development to ensure a smooth transfer to their production facility. MAST is not a product company.

Concerning Energy Storage Solutions, MAST, working together with an energy storage company and a top U.S. utility, is providing sensor technology and overall system and product integration management for the practical realization of a new energy storage system. This system will enable lower costs than building new power generating plants.

Pertaining to its Magnetic Nanoparticle Detection Platform, MAST, working with a leader in the oil industry, has developed an instrument that detects breakthrough water in production oil wells through magnetic and optical sensor techniques.

Micromem Technologies, via Micromem Applied Sensor Technologies, Inc. (MAST), recently announced an update on the status of the ATRA 171 project it has been developing over the last 5 years with its oil company partner, Chevron Corporation (NYSE: CVX). With this agreement, the continuing pilot project is proceeding through on site well evaluation. Also, the commercialization plans for this technology are progressing.

Micromem Technologies, Inc. (MMTIF), closed Wednesday's trading session at $0.0275, up 41.0256%, on 976,206 volume with 17 trades. The average volume for the last 3 months is 509,823 and the stock's 52-week low/high is $0.010499999/$0.128099992.

Sutter Gold Mining, Inc. (SGMNF)

Penny Stock Hub, Stockhouse, Streetwise Reports, InvestorsHub, 4-Traders, MarketWatch, Investors Hangout, Cardinal Weekly, TradingView and The Northern Miner reported on Sutter Gold Mining, Inc. (SGMNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sutter Gold Mining, Inc. engages in the exploration of mineral properties. The Company primarily explores for gold deposits. Sutter currently controls a considerable land position of the Mother Lode in California. The Company has advanced work and exploration programs completed on surrounding land holdings. Sutter Gold Mining has its management office in Lakewood, Colorado. It has its mine office in Sutter Creek, California. The Company lists on the OTC Markets Group’s OTCQB.

Sutter Gold Mining has two projects. One is the Lincoln Project situated in Amador County, on the California Mother Lode Gold Belt. The other is the Santa Teresa Project situated in the Northern Baja area of Mexico.

Regarding Mexico and the Santa Teresa Concession, the Company entered into an exclusive option agreement with The Alamo Group in October of 2006 to acquire a 100 percent interest in the Santa Teresa Mineral Concession. Santa Teresa is in the historic El Alamo gold mining district, southeast of Ensenada. The property is positioned contiguous to and on strike with the past-producing Princessa Mine.

Sutter Gold released in 2009 the assay results from the initial 32-hole Phase 1 program. The results included intercepts as high as 21.10 grams per ton or 0.62 ounces of gold per ton across 1.35 meters and 16.68 g/t of gold across 3.1 meters. These results continued to reveal the potential of this underexplored district. In addition, the results confirmed manifold high-grade veins up to 260 meters along strike from the historic Princessa Gold Mine and that all known structures remain open in all directions.

Sutter Gold Mining also holds the rights to the geologically similar, high-grade El Alamo district of northern Baja in Mexico. This is where historic mining to the water table produced mined grades of 30 to 60 g/t gold.

Regarding the Sutter Gold Project, California, the Lincoln and Comet properties are located on a 551-acre block of mining claims and surface rights 45 miles east southeast of Sacramento, California, in the central part of the 121-mile-long Mother Lode gold belt.

Sutter Gold Mining, Inc. (SGMNF), closed Wednesday's trading session at $0.01, up 181.6901%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 32,363 and the stock's 52-week low/high is $0.000000999/$0.0147.

MetaStat, Inc. (MTST)

Goldman Small Cap Research, Innovative Marketing, Club Penny Stocks Network, OTCBB Journal, First Penny Picks, StocksImpossible, Pumps and Dumps, and The MicrocapNews reported previously on MetaStat, Inc. (MTST), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter. 

OTCQB-listed, MetaStat, Inc. is a personalized medicine company developing therapeutic and diagnostic treatment solutions for cancer patients. The Company develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis - the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.  MetaStat’s focus is on breast, prostate, lung, and colorectal cancers, where systemic metastasis is responsible for approximately 90 percent of all deaths.

A life sciences company, MetaStat is headquartered in Boston, Massachusetts. In essence, MetaStat’s core expertise includes an understanding of the mechanisms and pathways that drive tumor cell invasion and metastasis, and also drug resistance to certain targeted therapies and cytotoxic chemotherapies.

The basis of MetaStat’s function-based diagnostic platform technology is on the identification and understanding of the vital role of the mena protein and its isoforms  (a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors).

The design of the MetaSite Breast™ and MenaCalc™ product lines are to accurately stratify patients based on their individual risk of metastasis and to enable clinicians to better customize cancer treatment decisions through positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the damaging side effects and cost of chemotherapy. 

The MetaSite Breast™ test measures the process of systemic metastasis. MenaCalc™, a platform of diagnostic assays, based on the measurement of the balance of the Mena protein isoforms, is widely applicable in solid epithelial-based cancers.

The intention of the MetaSite Breast™ test is for use in patients with early stage (stage 1-3), invasive breast cancer who have node-negative or node positive (1-3), estrogen receptor-positive, HER2-negative disease.

In August of 2017, MetaStat announced that accomplished drug developer, Renato T. Skerlj, Ph.D., joined the Company as a member of its Scientific and Clinical Advisory Board. Dr. Skerlj has more than 25 years of pharmaceutical experience in drug development resulting in two marketed drugs: Invanz® and Mozobil® and numerous drugs in clinical development.

He serves as Vice President of Drug Discovery and Preclinical Development at Lysosomal Therapeutics Inc. Dr. Skerlj is a Co-Founder and a Member of the Scientific Advisory Board of X4 Pharmaceuticals, Inc. He is also Co-Founder of Noliva Therapeutics.

MetaStat, Inc. (MTST), closed Wednesday's trading session at $0.035, up 400.00%, on 20,000 volume with 1 trade. The average volume for the last 3 months is 670 and the stock's 52-week low/high is $0.0023/$0.039999999.

The QualityStocks Company Corner

Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. To view the full article, visit http://ibn.fm/7UULj

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.


Recent News

chart

Deltec Bank & Trust Ltd.

The QualityStocks Daily Newsletter would like to spotlight Deltec Bank & Trust Ltd..

Deltec Bank & Trust, recently named the Best Private Bank Caribbean 2020 (http://ibn.fm/PS1F4), has published its latest investment research note entitled “EUreka” (http://ibn.fm/UhKNZ). In the piece, Deltec looks into the intricacies around the European Union’s (“EU”) proactive fiscal response in dealing with the ongoing coronavirus outbreak and its impact on Eurozone financial-asset prices and the Euro. To view the full article, visit http://ibn.fm/L6RVF

Deltec Bank & Trust Ltd. is a leading financial hub for global investors, financiers and entrepreneurs. The private and corporate bank offers its clients a unique suite of bespoke financial solutions, institutional expertise and highly attentive service with an aim toward creating a network of opportunities to enhance client wealth. Deltec Bank & Trust Ltd. is the flagship company of the Deltec International Group, a diversified independent financial services group providing a range of financial services including fund administration, corporate advisory, merchant banking, global insurance and digital asset solutions.

Founded in 1959, Deltec draws upon the collective experience of more than 150 professionals. These specialists come from a wide array of backgrounds, including private bankers and investment advisors, trust officers, lawyers and certified public accountants, many of whom have previously worked at some of the world’s largest and most prestigious financial institutions. Deltec specializes in providing its clients with private banking and fiduciary expertise, fund administration, investment management solutions, digital asset financial services, insurance, and corporate and merchant banking capabilities.

Following the purchase of Société Generale’s private banking business in The Bahamas in 2016, Deltec has seen its group-wide assets under management, administration and custody rise to over $12 billion, as of late 2019 (http://nnw.fm/n0YQx).

Deltec Bank has received a number of accolades throughout its lengthy history, most recently being named the ‘Best Private Bank in the Caribbean 2020’ by Global Banking and Finance Review (http://nnw.fm/jx4rS), an award which it also won in 2015. The company was recognized for its outstanding performance and achievements, scoring particularly highly in the following categories:

  • Strong client relations with personal and client-focused services;
  • Highly personalized and innovative products and services; and
  • Continued commitment to providing clients with the best possible financial solutions.

Opportunity within Fintech

Remarkably for a private bank, Deltec Bank & Trust has historically been at the forefront of the digital banking and fintech revolution within the financial services industry. Deltec has also gained renown for its annual conference, with the latest iteration focusing on disruption with financial services (http://nnw.fm/3m0kX). Hosting over 300 delegates, including the Deputy Prime Minister & Minister of Finance of The Bahamas, the conference featured ‘The Innovator’s Marketplace’, a forum providing an opportunity for emerging companies in biotech/life sciences, virtual reality, blockchain, fintech, quantum computing and other cutting-edge industries to pitch their ideas to investors and attendees in 45-minute presentations.

Engagement with the Community

Deltec Bank has long held strong ties within the local community in The Bahamas through its Deltec Initiatives Foundation, which was designed to foster an environment that empowers young Bahamians to drive positive social impact through the power of arts, entrepreneurship and education.

Since 2013, the foundation has discovered, launched and mentored many talented, motivated and driven Bahamian artists, artisans and entrepreneurs. The Deltec Initiatives Foundation comprises three pillars: The Initiative for the Arts, The Initiative for Young Entrepreneurs and The Initiative for Scholarship & Education.

Expert Team of Professionals

Jean Chalopin, chairman of Deltec International Group, is a global business leader with a remarkably diverse background encompassing several industries, including banking, wealth management, biotechnologies and entertainment.

Odetta Morton, CEO of Deltec Bank & Trust, is a seasoned banker and CPA with over 20 years of experience in the financial services sector, including financial management, shareholder relations, business leadership and corporate strategy.

Gregory Pepin, Deputy CEO of Deltec Bank & Trust, is an expert financial strategist with vast experience in blockchain technology, investments, wealth management and insurance.

Fabio Gama, Chief Operating Office of Deltec Bank & Trust, has 15 years’ experience in the financial services industry, Fabio has been directly responsible for operations, IT, facilities and procurement. He is an expert in developing teams and has a proven track record for supporting business needs.

Tanya Carey, Chief Financial Officer of Deltec Bank & Trust, is a resourceful finance professional and licensed CPA with over 20 years of experience in financial services and solid industry and regulatory knowledge.

Terry Girling, Chief Administrative Officer of Deltec Bank & Trust, is a senior executive, chartered accountant and banking professional with over 40 years of experience in the finance and banking sectors. Girling is experienced in all facets of banking, including accounting, compliance, operations, technology, fund administration, trust administration and human resources.

Hugo Rogers, Chief Investment Officer of Deltec Bank & Trust, is a multi-asset investment and award-winning global equity and hedge fund manager. He has actively managed investments for over 15 years. He is also a CFA Charterholder with a master’s degree from Oxford University.


Recent News

chart

Pac Roots Cannabis Corp. (CSE: PACR)

The QualityStocks Daily Newsletter would like to spotlight Pac Roots Cannabis Corp. (PACR).

Pac Roots Cannabis Corp. (CSE: PACR) was featured today in the 420 with CNW by CannabisNewsWire. With medical marijuana now legal in 33 states and recreational marijuana is making inroads into the law books of more than a dozen states, the following tips might come in handy, whether you grow cannabis for personal use or for a dispensary.

Pac Roots Cannabis Corp. (CSE: PACR) is a Canadian cannabis company dedicated to producing premium-quality strains and products by leveraging a genetics-focused approach.

The company began operations in 2012, with activities primarily directed toward exploration and development of mineral properties in Canada. Today, it is focused on cannabis and hemp cultivation, leveraging high-end genetics and specialized cultivars to produce top quality products. Pac Roots has announced multiple promising initiatives in recent months, including its formation of an outdoor premium hemp joint venture with partner Rock Creek Farms in British Columbia, Canada, and its agreement to acquire all issued and outstanding shares of a firm holding 250 acres of land in the famed Fraser Valley Region of British Columbia.

Pac Roots is also in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through an elite line of 350+ unique, high-grade cultivars. Pac Roots expects to receive a cultivation license for the facility in the fourth quarter of 2020.

High-End Selectively Bred Genetics

Pac Roots focuses on high-end genetics in order to maximize the quality of its products while maintaining high yields and profit margins.

Through the process of artificial selection, farmers and cultivators have been adapting their plants to develop particular phenotypic traits for generations. Historically, this practice was restricted to underground cannabis producers developing their own strains.

The legalization of the cannabis industry has given producers access to thousands of cultivars located throughout the world while accelerating research into cannabis genetics. By carefully selecting strains, growers can control the size, color, smell, density and texture of cannabis buds, thereby creating distinctive, premium cannabis products.

Plants are bred to thrive in specific growing environments. This maximizes the yield of high-quality, resilient cannabis. Medical cannabis strains can also be tailored for specific medicinal purposes.

A strategic partnership with Phenome One, a plant breeding management and analytics firm, gives Pac Roots access to some of the world’s best cannabis genetics from the largest genetic library in Canada. The company is using these genetics to develop unique strains featuring a variety of beneficial characteristics.

The company’s 350+ licensed live cultivars and over 1,800 seed varieties are the result of a meticulous gene selection process, through which as many as 600 individual plants may be grown to produce a single strain. Selecting optimized genetics in this way provides benefits beyond simply producing a high-end product. In addition to potency and bud quality, cannabis plants are bred for yield and resilience. By selecting genetics that result in larger and more numerous buds on each plant, Pac Roots is able to grow more cannabis per grow light.

Breeding plants to be more resilient also reduces the cost and labor required. These factors, combined with the premium price point associated with top-quality cannabis, have the potential to improve Pac Roots’ overall profit margin.

Partnership with Phenome One

Pac Roots has secured its cultivars through a strategic licensing agreement with Phenome One. Under the agreement, Pac Roots has unlimited access to Phenome One’s live genetic library, including any of Phenome One’s cultivars and its growing, breeding and cloning IP.

Phenome One is an agricultural technology company focused on providing software solutions to seed companies. Phenome One’s platform gives its partners access to a massive database of detailed information on over 350 unique cannabis cultivars to support each stage of the breeding process. Each cultivar has been laboratory analyzed and rigorously field-tested, with data going back more than 30 years.

Using Phenome One’s data, Pac Roots plans to grow a variety of cannabis plants optimized for certain traits. One such trait will be plants with an abundance of cannaflavin, a rare terpene with high anti-inflammatory properties. Phenome One’s library could enable Pac Roots to produce plants that are bred to thrive in a range of different growing climates, including plants suited to grow in cold weather and plants that are resilient to region-specific fungi.

Joint Venture with Rock Creek Farms of British Columbia

Pac Roots recently entered a definitive investment agreement with Rock Creek Farms, a reputable agricultural enterprise, for a 100-acre commercial hemp operation in Rock Creek, British Columbia. The growing space is located in the highly lucrative farming area known as the ‘Golden Mile’ in the South Okanagan Valley of British Columbia. (http://nnw.fm/Gbf9I).

Under the agreement, the two companies have formed an outdoor premium hemp joint venture company to which Pac Roots is providing an aggregate of $450,000 in capital and Rock Creek Farms is contributing two commercial leases for 100+ acres of growing space, along with cultivation licenses, agricultural infrastructure and equipment, consulting services, intellectual property relating to hemp operations and proprietary biomass storage methods. Pac Roots holds a 60 percent interest in the project.

About 127,500 premium hemp CBD seedlings were planted across 100 acres as of early July 2020. The joint venture is planting a premium grade CBD hemp variety utilizing the rich native soil and both traditional and custom farming techniques.

“Our operational partners at Rock Creek Farms bring decades of generational farming expertise in one of Canada’s pre-eminent growing regions,” Pac Roots President and CEO Patrick Elliott said in a news release detailing the venture. “It will be an exciting outdoor growing season for the joint venture as we anticipate a successful harvest in the fall.”

Infinite Development Possibilities at Fraser Valley Property in British Columbia

In mid-July 2020, the company initiated a share purchase agreement with 1088070 BC. LTD. (“1088”) and its shareholders for the acquisition of all issued and outstanding shares of 1088 (http://nnw.fm/xlpw7). Notably, 1088 owns and controls 250 acres of land spread over nine parcels in the Fraser Valley Regional District.

The Fraser Valley Regional District is one of the most productive and intensively farmed areas of Canada, offering access to high-quality soil, favorable climate, water and a local market of 2.5 million people. Agriculture in this region yields an annual economic value of more than $3 billion.

The closing date for the transaction is slated for September 4, 2020, after a 51-day due diligence period. According to Elliott, the addition of such a significant package of land is a major step for Pac Roots.

“This land has no zoning restrictions and is not situated within the agricultural land reserve, which provides for infinite development possibilities,” Elliott added in a July 2020 news release.

Board of Directors member Chad Clelland also welcomed the acquisition, adding that between Fraser Valley and Rock Creek – both of them among the most productive agricultural regions in Canada – Pac Roots is very well positioned for production and the future development of its hemp and cannabis infrastructure.

The RAD Americas Genetic Program – Research and Development in Americas Genetic Program

Pac Roots intends to deploy a global R&D program focused on rigorously testing elite strains in various rich agricultural regions throughout the Americas, with a goal of mass selection to achieve the utmost environmental resilience while achieving notable quality and yields. From seed to software, collection data, proprietary techniques and custom nutrient formulas, Pac Roots and Phenome will provide the specific knowledge to cultivators in different climates in order to achieve optimal yields for THC, CBD, CBG and other unique cannabinoids. R&D from global testing programs situated throughout the Americas will allow the partnership to deploy and stress test a range of suitable cultivars in the world’s lowest cost outdoor growing regions.

The company expects an industry shift in 2020 from the COVID-19 global pandemic. The ‘new normal’ will bring more focus on efficiencies and optimal yields to deliver a cost effective, high quality product to the end user. There has been much to be learnt from the inefficiencies in the cannabis industry in recent years, which have been detrimental to the credibility of the sector. Pac Roots is well positioned to enter the scene and take advantage of the deficiencies, reinforcing the notion that genetics and flawless growing techniques are paramount to success. Genetics and systems innovation may be the most overlooked components when comparing cannabis to other established agricultural crops. Pac Roots plans to invest into cannabis R&D to ensure a solid foundation is built that will be used by cannabis farmers worldwide.

Through its RAD Americas Development and Innovation, Pac Roots is focused on:

  • Deploying one of the largest live genetic libraries in Canada, diversified for high yield output and unique climates
  • Continued stress testing for indoor, high yield, THC and medicinal genetics
  • Continued stress testing for outdoor, high yield, THC and medicinal genetics
  • Exotic, genetic cloning for the luxury, high margin, cannabis flower market
  • Psychoactive/medicinal ratio testing for effect and
  • Unique Cannabinoid and terpene elevation and isolation.

Through its RAD Americas Field Testing System, the company is focused on:

  • Global testing in different microclimates to assess genetic and complete systems for optimal yields
  • Data collection, testing and optimization to prove process for commercial implementation and
  • High quality yield testing for THC, CBD, CBG and other unique medicinal cannabinoids.

Lake Country Cultivation Facility near Kelowna, British Columbia

Pac Roots is in the process of completing its 20,000 square foot cultivation facility in Lake Country, British Columbia. The facility is expected to feature approximately 7,600 square feet of cultivation space that will enable the company to cycle through its line of high-grade cultivars. Pac Roots plans to submit a video evidence package of the facility build under Health Canada’s Cannabis Tracking and Licensing System, and the company expects to acquire its cultivation license in the fourth quarter of 2020.

Lake Country is a municipality located just outside of Kelowna in the Okanagan region of British Columbia. For decades, the region’s favorable growing climate has made it a hub for cannabis cultivation. As the Canadian legal cannabis industry ramps up, the Okanagan region is attracting attention from dozens of cannabis companies, including some of the industry’s biggest names. The region’s strong agricultural history has left it rich with experienced agricultural workers and an abundance of Agricultural Land Reserve (ALR) property.

Management Team

Patrick Elliott, MSC, MBA, President and CEO of Pac Roots Cannabis, is also the President & CEO of Lexore Capital Corp., a private resource and cannabis investment company, as well as Phenome One Corp., a full-service cannabis farming company focused on elite strain selective breeding. Elliott brings over 15 years of corporate finance, mineral exploration and financial markets experience to the Pac Roots team. He is a graduate of the University of Western Ontario in geology and holds an MSc. in mineral economics and an MBA from Curtin University of Technology in Perth, Australia. Elliott specializes in economic resource evaluation, financial modeling, CAPEX estimation, corporate development and finance. Combined with his technical knowledge, Elliott has a wealth of contacts in the financial sector.

Marc Geen, Founder and Strategic Operations Advisor, is a fourth-generation British Columbia farmer who has been active in the legal medical marijuana industry for more than 10 years – consulting on, complying with, and participating in the MMAR, MMPR and ACMPR programs. Prior to co-founding Speakeasy Cannabis Club Ltd., Geen spent 14 years as Head of Operations for Kettle Mountain Ginseng Ltd., one of North America’s largest ginseng producers. With the experience gleaned from a long career in large scale commercial farming, Geen has been able to apply many cost-effective farming practices to the outdoor, indoor and greenhouse cultivation of cannabis. Geen is also the co-creator of a full line of cannabis extract products designed under ACMPR regulations.

Matt McGill, Director, has a strong background in both commercial and residential real estate and has played a major role in many development projects. McGill, through McGill Realty, has established a tremendous commercial and residential outfit servicing British Columbia’s Fraser Valley and the lower mainland. McGill is skilled at crafting strategic financing options for corporations and has a substantial network of retail and institutional clients.

Chad Clelland, Director, has experience in the sector dating back to 2009, when he purchased Medicalmarijuana.ca, which became an information portal for thousands of patients, doctors and growers. Through this company, he and his team have helped thousands of Canadians find legal, safe medication. His team also consulted, designed and submitted dozens of applications to the government under the MMPR, ACMPR and Cannabis Act. In 2011, Clelland co-founded Greenleaf Medical Clinic, which is now recognized as a training facility by the University of British Columbia and offers preceptorships to physicians, nurse practitioners and pharmacists. He also co-founded Folium Life Science in 2013, an approved Canadian Licensed Producer. His roles in these organizations have included Chief Operating Officer, head of security, alternate master grower and alternate responsible person in charge.

Josh Bromley, Senior Cultivation Strategist, is a second-generation farmer with over two decades of experience farming, breeding, cultivating and selecting unique cultivars for the medical community. He is an expert in plant science and possesses a comprehensive knowledge of cultivars and a mastery of medicinal implementation. Bromley has developed proprietary farming systems, as well as low cost/high output nutrient systems. Through thoughtful design and engineering, he has been able to consistently show improvements in crop yields, pathogen resiliency and quality.

Pac Roots Cannabis Corp. (PACR), closed Wednesday's trading session at $0.25, off by 12.28%, on 64,500 volume with 7 trades. The average volume for the last 3 months is 39,023 and the stock's 52-week low/high is $0.11/$0.72.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced that its products will be carried by Dot Foods Inc., the largest food redistribution company in the United States. This entry into the hospitality space includes the company’s Alkaline88(R) and A88 Infused(TM) lines as well as its aluminum bottles. A producer of premium bottled alkaline water, flavor-infused waters, and CBD-infused products, WTER said these products will be available nationwide to Dot Foods’ 4,300 customers around the country by Sept. 21, 2020. To view the full press release, visit http://cnw.fm/Ea73g.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Wednesday's trading session at $1.57, up 11.3475%, on 4,739,442 volume with 10,620 trades. The average volume for the last 3 months is 1,621,989 and the stock's 52-week low/high is $0.400000005/$2.79999995.

Recent News

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element (NASDAQ: NETE) was featured today in a publication by Green Car Stocks. You may not have considered buying an electric car probably because you lack enough information about them. Furthermore, several myths and misconceptions have been spread around, and these may have made you shy away from these vehicles. However, here are some of the facts that you did not know about electric cars.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Wednesday's trading session at $7.17, off by 5.1587%, on 207,512 volume with 1,456 trades. The average volume for the last 3 months is 1,717,087 and the stock's 52-week low/high is $1.472/$20.0783996.

Recent News

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, recently completed a round of successful fundraising that will assist in expanding the availability of its platform. DarioHealth secured approximately $28.6 million in aggregate gross proceeds from health-care funds and institutions across the United States and Israel through the private-placement transaction with accredited investors. The new capital coupled with existing cash  puts the company in its best financial state since its inception (http://ibn.fm/uKWvc). To view the full article, visit: http://ibn.fm/vtGXU. Also today, the company was featured in a publication from BioMedWire, examining how, as researchers are frantically looking for a COVID-19 vaccine and other treatments, safety, and health ethical issues of patients must be highly considered. Some ethical issues, like the anonymity of patients, must be handled with proper attention so as not to affect the esteem of any individual. As a researcher, before using any patient in your clinical trials, you must first obtain written consent from them. You may risk your job in acquiring the biospecimen from patients if you do not seek permission from them.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Wednesday's trading session at $16.50, off by 7.0423%, on 132,723 volume with 980 trades. The average volume for the last 3 months is 250,758 and the stock's 52-week low/high is $3.01999998/$22.4899005.

Recent News

Kingman Minerals Ltd. (TSXV: KGS)

The QualityStocks Daily Newsletter would like to spotlight Kingman Minerals Ltd. (TSXV: KGS).

Despite negative headlines focused on recent price drops (http://ibn.fm/XCUAS), the price of gold continues to set record highs, eclipsing the effects of recent volatility. Kingman Minerals (TSX.V: KGS), a Canada-based mining company focused on the acquisition, exploration and development of gold and silver properties in North America, is planning to increase gold production in anticipation of rising prices by sourcing and developing historic mining sites for new drilling campaigns that extract the remaining wealth using innovative, safe and cost-effective technology.

Kingman Minerals Ltd. (TSXV: KGS), formerly Astorius Resources Ltd., is engaged in the acquisition, exploration and development of gold and silver properties in North America. The Canada-based company is focused on sourcing and developing high-quality properties in favorable mining locations to advance its diverse portfolio of low-cost, lifelong assets.

Kingman Mine

The Company maintains the following projects:

The Mohave Project: Located in the Music Mountains in Mohave County, Arizona. Approximately 35 miles from the town of Kingman, the property consists of 20 lode claims, including the historic Rosebud Mine. The Company has entered into an option agreement to earn 100% over four years. According to historic mappings of the mine, probable ore is 15,560 tons. Possible (inferred) ore is comprised of 176,000 tons, and additional possible (inferred) ore totals slightly over 1,100,000 tons. The total contained gold ounces for all categories is estimated at 664,000 ounces, and contained silver is estimated at 2,600,000 ounces. The Company has recently completed two underground reconnaissance and sampling programs and is in the process of verifying previous resource estimates.

 

The Cadillac East Property: Located approximately 55 kilometers east of Val d’Or, a hub for exploration and mining activities in the Canadian province of Quebec. The Company acquired a 100% interest in the property from an arm’s length vendor. Cadillac East Property consists of 12 claims, and the Company has an option agreement to earn 100% over three years. Having been the subject of numerous geophysical and geological surveys, the Cadillac East Property has been explored and surveyed by numerous companies as well as by the Quebec government. Exploration work done in 2017 by Exploration Facilitation Unlimited Inc. revealed multiple potential targets for future investigation, as results from the soil program identified value in gold, silver, copper, zinc and nickel.

Kingman Minerals is focused on enhancing shareholder value as it continues exploring potential assets and acquiring strategic gold targets. The company recently commissioned mining consulting services company Burgex Mining Consultants Inc. to complete two underground gold exploration programs in the historic Rosebud Mine. Burgex specializes in mineral exploration, mining claim staking, landman services, mining consulting, and the access and documentation of abandoned mine sites throughout the western United States and the world. Burgex’s founders have been active in the industry since 2007 and have identified, secured and consulted on hundreds of thousands of acres of mineral properties spanning a wide range of mineral commodities with billions of dollars’ worth of resources and reserves. The Burgex team has been featured in Forbes Magazine as well as on the Discovery Channel and other outlets. Burgex is at the vanguard of industry advancements in safely accessing difficult vertical abandoned mine workings and continues to pioneer new mineral exploration methods with strategic partners throughout the United States and the world.

Gold’s Predicted Rise

The value of gold is currently on an upward climb due to COVID-19’s upending of the global economy, causing governments to expand their balance sheets. In 2019, as a result of the housing and financial crisis, gold saw its best performance since 2010 — increasing as much as 20% and hitting a top price of $1,549 per ounce in September of that year. Analysts predict its price will continue to climb due to strong buying by central banks, a weakening of the U.S. dollar, and increasing political tensions. A recent Wolfe Research report predicted gold would hit an all-time high, referencing an ounce of gold that commanded a $1,515 asking price. As the value of the U.S. dollar weakens, the demand for gold is inversely rising. Known as a safe-haven asset, gold tends to see increased levels of demand during times of consumer fear or recession.

Management

Sandy MacDougall – Chairman and Director
An economics graduate from the University of British Columbia, Sandy MacDougall brings 30+ years of experience in the investment banking and finance industry to KGS. He was instrumental in the acquisition, development and production of gold at the Alto el Toro mine near Ibaguel, Columbia. As a former investment advisor at Canaccord Capital Corp., MacDougall was a key player in multiple significant financings in Canada as well as abroad, working with a wide range of companies. His experience has afforded him critical exposure to precious and base metal projects throughout North and South America, and he has served as chairman of the board since 2016.

Arthur Brown – President and Director
With 36 years of business experience and service to the boards of eight other companies in sectors ranging from technology to oil, gas and mineral exploration, Arthur Brown adds substantial knowledge in corporate structure and development as well as financings and venture capital to the KGS team.

Cyrus Driver – Independent Director
Cyrus Driver was a founding partner in the firm of Driver Anderson from its inception in 1982 and is a chartered accountant as well as a retired partner in the firm of Davidson and Company LLP. Aside from providing general public accounting services to a diverse range of clients, his specialty is servicing TSX Venture-listed companies and members of the brokerage community. With expert knowledge of the securities industry and its regulations, Driver lends valuable advice to his clients regarding finance, taxation and other accounting-related matters. He currently serves as director and chief financial officer of several TSX-V-listed companies.

Dr. Peter Born – Director and Technical Specialist
A professional geologist registered with the Association of Professional Geoscientists of Ontario and a fellow of the Geological Association of Canada, Dr. Peter Born brings 30+ years of experience in exploration and mining to the company. With prior roles as a senior geologist with Western Mining Corporation, he is currently working with RPS Energy Canada Ltd. on natural gas plays related to high-temperature dolomites and sedimentary zinc deposits (MVT) within the Appalachian Basin in the United States. Dr. Born holds a Ph.D. in earth sciences and has expertise in Precambrian sedimentary geology, basin analysis, sedimentology, stratigraphy and sedimentary ore deposits.

Kingman Minerals Ltd. (TSXV: KGS), closed Wednesday's trading session at $0.095, off by 5.00%, on 28,000 volume with 2 trades. The average volume for the last 3 months is 105,875 and the stock's 52-week low/high is $0.07/$0.23.

Recent News

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, has announced that CEO Mark S. Chalmers has been invited to be a presenter at this year’s virtual LD 500 investor conference. During his presentation, Chalmers will provide an update on the company. The presentation will include an overview of UUUU’s critical mineral initiatives, including uranium production; it will also include discussion on the company’s strategic plan to eliminate debt and its progress with the rare earth element ("REE") processing program. To view the full press release, visit http://ibn.fm/DW3UE

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Wednesday's trading session at $1.80, up 4.6512%, on 3,338,372 volume with 8,024 trades. The average volume for the last 3 months is 1,469,356 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

InsuraGuest Technologies, Inc. (TSX.V: ISGI)

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Technologies, Inc. (TSX.V: ISGI).

Innovative insurtech leader InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF) appears set to bolster its presence in the vacation-rental market. The company has completed the integration of the end-to-end, property-management platform operated by Hostfully Inc. with InsuraGuest’s Application Programming Interface (“API”) (http://nnw.fm/Jb7g1). 

InsuraGuest Technologies, Inc. (TSX.V: ISGI) is a leading global SaaS (Software-as-a-Service) company leveraging its proprietary, flagship insurtech (insurance + technology) software, InsuraGuest, which is integrated with the property management systems of hotels and vacation rentals to deliver custom Hospitality Liability coverages.

InsuraGuest’s Hospitality Liability coverages are purchased by hotels and vacation rental properties, which can address claims from guests and their room occupants. The combination of the integrated software and customized insurance provides the property liability coverages the guests benefit from in the event a loss is incurred during their stay.

The Hospitality Liability policy is offered through integration of InsuraGuest’s API with the clients’ property management systems. InsuraGuest’s platform is currently capable of integrating with approximately 71 different hotel and vacation rental property management systems, giving it access to millions of rooms worldwide.

InsuraGuest continues to pursue expansion opportunities in the United States, and has plans to expand to its distribution platform and Hospitality Liability coverages to the United Kingdom and Europe regions by third quarter 2020, as well as expansion into Asia by the end of 2020.

Protection that Enhances the Guest’s Experience

InsuraGuest’s Hospitality Liability coverages add a layer of protection for the property on a primary basis, should a guest experience an accident or theft while staying at an InsuraGuest member hotel or vacation rental property.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights stayed in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion stayed nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United States, where there approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit that are not the properties fault.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Hospitality Liability policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Investment Consideration

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a Bachelor of Science in consumer studies with an emphasis in architecture as an undergraduate at the University of Utah. He subsequently earned his MBA. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Logan Anderson, CFO & Director
Logan Anderson (bachelor’s degree in communications, accounting and economics) holds the designation of ACA with the Chartered Accountants of Australia and New Zealand. He began his career as an associate chartered accountant in New Zealand and then Canada. This was followed by his position as controller of a management services company which was responsible for the management of numerous private and publicly traded companies. Since 1993, Anderson has served as president of Amteck Financial Corp. (and its predecessors), a private financial consulting services company servicing both private and public companies. He is a former director of 3D Systems, Inc. (NYSE: DDD), and was formerly a founder, officer, and director of Worldbid.com. Anderson has also been involved in raising funds for numerous private and public companies in all stages of their development and has been an officer and director for numerous public and private companies over the past 40 years.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends. Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Tony Sansone, COO & VP of Finance
Tony Sansone has over 30 years of financial, operations and business development experience which includes serving as CFO in the health care, foodservice distribution, manufacturing and technology sectors, including public company experience. He has held senior finance positions in the banking, telecommunications, medical products, and food & drug retailer industries, closing over $430 million of private debt, equity and line of credit financings and over $350 million of a merger, acquisitions, real estate and state incentive transactions, including due diligence, negotiations, closing, and integration. Sansone coordinated and was the executive sponsor for four ERP implementations and multiple other best-in-class software & technology solutions. He received his MBA from the University of Utah and a Bachelor of Science in accounting from Utah State University. Sansone also currently serves as president-elect of the Utah Chapter of Financial Executives International and a past president and current member of the board of trustees for Catholic Community Services of Utah. He is the proud father of three children.

Christopher J. Panos, Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018 and as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Jennifer Epperson, Vice President of Sales
Jennifer Epperson has over 20 years of B2B sales experience with exceptional success history. She has grown and developed sales territories across multiple industries. Her ability to find and develop strategic relationships has given her top-level performance throughout her career. Epperson’s passion and knowledge provide an inherent ability to connect and retain relationships for the growth of the company. Throughout her professional career, she has achieved peak performance sales results and awards year after year. She captures the vision of the company and drives it forward with enthusiasm and expertise. Her commitment to providing an exceptional customer experience has been the key to her success.

Richard Matthews, Interim Financial Controller
Richard Matthews joined the InsuraGuest team in March 2019 as the interim financial controller. Leading the Finance and Audit team, Matthews is responsible for the delivery of financial services such as accounting, treasury, reporting, budgeting and insurance management, in accordance with legislative requirements and organizational policies and strategies. He has over 30 years of experience in providing professional services across a broad range of finance areas including compliance, business process, audit, and financial reporting. He holds a degree in accounting from the University of Utah and is a licensed CPA in the state of Utah.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.

Jim Kilduff, Board Advisor
James “Jim” C. Kilduff has nearly 40 years of experience in the insurance and risk management sectors. He is a dynamic and energetic team leader and builder with extensive experience in the changes affecting the insurance business through Gas, alternative distribution, insurtechs and program business. His skillset includes experience as chief insurance officer with Outdoorsy Insurance Group, CEO with Harbor Hill Solutions Inc., and senior vice president and chief marketing officer with State National Insurance Companies. His career has spanned MGA creation and management, insurance company management, business development and underwriting, primary insurance and reinsurance.

Don Archibald, Board Advisor
Don Archibald brings to InsuraGuest’s advisory board 54 years of experience as an insurance agent. Archibald is the founder and former owner of Archibald Clarke and Defieux (ACD Insurance), as well as the co-founder and former equity partner of Sussex Insurance, and an agent with Sussex since 2014.

InsuraGuest Technologies, Inc. (TSX.V: ISGI), closed Wednesday's trading session at $0.15, even for the day, on 6,000 volume. The average volume for the last 3 months is 297 and the stock's 52-week low/high is $0.079300001/$0.248799994.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses the power of an individual patient’s tumor to personalize their cancer treatment plan. Also today, the company was featured in a publication from BioMedWire, examining how the use of artificial intelligence (“AI”) has increased over the years. This has enabled researchers to have the computing powers of higher orders than what was there when COVID-19 first struck. Today, artificial intelligence has significantly been used to find different patterns within large information sets. Furthermore, artificial intelligence is instrumental in helping you to understand better any information that is not characterized. AI can also be used in predicting trends and patterns of the various phenomenon, and this could hold the key to finding a solution to COVID-19.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Wednesday's trading session at $1.17, off by 0.847458%, on 300,798 volume with 590 trades. The average volume for the last 3 months is 990,760 and the stock's 52-week low/high is $1.10000002/$6.25.

Recent News

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs, Inc. ("Sigma Labs" or the "Company") (NASDAQ:SGLB), a leading developer of quality assurance software for the additive manufacturing industry, will participate in the following investor conferences during the month of September 2020: the LD 500 Virtual Investor Conference on September 1-4, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Wednesday's trading session at $2.59, off by 9.7561%, on 2,478,151 volume with 7,223 trades. The average volume for the last 3 months is 1,386,112 and the stock's 52-week low/high is $1.97000002/$11.6999998.

Recent News

Wrap Technologies Inc. (NASDAQ: WRTC)

The QualityStocks Daily Newsletter would like to spotlight Wrap Technologies Inc. (NASDAQ: WRTC).

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced its receipt of the first purchase orders for BolaWrap products and accessories from agencies in the states of Nevada and Arkansas. According to the update, the company has received initial and repeat purchase orders from law enforcement agencies across 13 states since the beginning of July. As a result, the company has provided BolaWrap devices to more than 215 agencies across 44 states. To view the full press release, visit http://nnw.fm/qat7G

Wrap Technologies Inc. (NASDAQ: WRTC) is an innovator of modern policing solutions. The company’s BolaWrap® product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a range of 10-25 feet. Developed by award-winning inventor Elwood Norris, the company’s chief technology officer, the small-but-powerful BolaWrap assists law enforcement in safely and effectively controlling encounters, especially those involving an individual experiencing a mental crisis.

Non-Lethal Weapons Market Potential

The BolaWrap Remote Restraint device is an innovative police solution, designed to provide law enforcement with a unique mobile and humane restraint option that does not inflict pain and enables subjects to be detained from a distance without the use of force.

In 2015, the 10 cities with the largest police departments in the United States paid out a cumulative $248.7 million in settlements and court judgements in police misconduct cases, marking a 48% increase from the $168.3 million in 2010 (http://nnw.fm/ri0L9). The majority of these cases have centered around the improper use of force by law enforcement when subjugating individuals, with 25% of all fatal shootings by law enforcement in the United States reportedly involving mentally ill individuals who are often incapable of comprehending officer commands (http://nnw.fm/YVm8P). Moreover, the use of alternate devices has failed to produce the desired outcomes, with the use of tasers by police resulting in over 1,080 fatalities since 2000 (http://nnw.fm/2Nb1A).

This, in turn, has led to a greater demand for humane tools which are not reliant on pain compliance to subdue subjects. Since its IPO in December 2017, Wrap Technologies has enjoyed a spectacular rise in prominence. The company began field testing the BolaWrap product in July 2018, with the first international order received only a month later, in August 2018. By December 2018, the company had been uplisted to the Nasdaq Capital Market with over 1,000 shareholders – a significant increase from the 50 shareholders who had participated in the IPO just 12 months prior. Recently, the company has sought to increase its commerciality and product monetization, appointing Tom Smith, the founder of TASER International (now Axon, NASDAQ: AAXN), as its president in March 2019.

At present, over 140 police departments throughout the United States are actively carrying the BolaWrap, while over 1,700 police departments across the nation have reached out to the company to request BolaWrap demonstrations, training and quotes. BolaWrap has also been successfully marketed internationally and has been shipped to 19 countries thus far.

As of today, Wrap Technologies has built a network of 11 distributors across 45 states in the United States who are actively marketing the product to the over 900,000 active police officers in the country. In addition, the company now has a network of 15 international distributors based in 26 countries – with over 600 international requests received thus far for product demonstrations, training and quotes.

As a result and following the opening of its new 11,000-square-foot manufacturing facility in Tempe, Arizona, in October 2019, Wrap Technologies announced a 352% year-on-year increase in revenues for 3Q2019 – a testament to the growing popularity of its mobile restraint device.

The company expects its growth to continue as adoption rates of the BolaWrap product increase throughout the United States and globally. According to a study by Stratistics MRC, the addressable global market for non-lethal weapons accounted for $6.32 billion in 2016 and is set to rise to $11.85 billion by 2023.

Product Received to Positive Acclaim

  • “An innovation that is changing the world of policing.” – Chief Luther Reynolds, Charleston Police Department
  • “Anytime you can have a more humane response to someone in crisis, it’s not only good for the department, it’s good for society.” – Redditt Hudson, Regional Field Director of the NAACP (http://nnw.fm/1STXm)
  • “This is going to save lives.” – Chief Ed Hudak, Coral Gables Police Department
  • “I see this as one of the great tools if you encounter someone with a mental health crisis.” – Chief Steven Casstevens, Buffalo Grove Police Department

Recently completed $12.4 million financing round

Wrap Technologies announced that it had successfully completed its capital raising round on June 4, 2020, raising $12.4 million through a primary share placement priced at $6.00/share. The net proceeds will be use to further scale engineering, fund product development and provide working capital to meet worldwide demand for BolaWrap products and accessories (http://nnw.fm/byLV7). The company also announced that its founder, Elwood Norris, had chosen to exercise 100,000 outstanding warrants to contribute $500,000 to the capital raising efforts. Following the financing round, Wrap Technologies reported over $30 million in cash on hand.

Management Team

Elwood G. “Woody” Norris, Founder and Chief Technology Officer
Elwood G. “Woody” Norris is an award-winning American inventor and serial entrepreneur and currently serves as chief technology officer for Wrap Technologies Inc. Norris founded and served as a director and president of Parametric Sound Corporation (now Turtle Beach Corporation (NASDAQ:HEAR)) and also served as chief scientist at Turtle Beach. Norris previously founded LRAD Corporation (NASDAQ: LRAD) and, prior to retiring in 2010, was chairman of LRAD Corporation’s board of directors, serving as a technical advisor and product spokesperson. Norris has authored more than 80 U.S. patents, primarily in the fields of electrical and acoustical engineering, and has been a frequent speaker on innovation to corporations and government organizations. He is the inventor of Wrap Technologies’ patented and patent pending BolaWrap® technology.

Scot Cohen, Executive Chairman
Scot Cohen has more than 20 years of experience in institutional asset management, wealth management, and capital markets. Cohen founded and served as principal of the Iroquois Capital Opportunity Fund, a closed-end private equity fund which focused on investments in North American oil and gas. Cohen also co-founded Iroquois Capital, a New York-based hedge fund that managed approximately $300 million across its family of funds. Prior to Iroquois Capital, Cohen founded a merchant bank which actively participated in structured investments in public companies. Cohen is currently active on a number of public and private company boards and is involved with various charitable ventures.

David Norris, Chief Executive Officer
David Norris is an experienced executive who joined Wrap Technologies full-time in January 2018. From April 2014 to December 2017, he served in various executive roles, including president, at privately held loanDepot LLC as it rapidly expanded into the fifth largest mortgage lender in the U.S. loanDepot had 6,000 employees and generated $1 billion in revenue in 2017. Norris also served as CEO of Greenlight Financial, and president of LendingTree Loans. Norris’ career also includes executive and management roles at Toshiba America Information Systems and Qualcomm Personal. Earlier in his career, Norris served as a probation officer in San Diego for five years.

Tom Smith, President
Tom Smith co-founded TASER International (now Axon Enterprise Inc. (NASDAQ: AAXN)) (“TASER”) in 1993 and served as president of TASER until October 2006. He served as chairman of the board of directors of TASER from October 2006 until he retired to pursue entrepreneurial activities in February 2012. Amongst his most significant roles and responsibilities at TASER, Smith managed domestic and international sales, significantly expanding the sale and distribution of TASER’s products, including sales to more than 17,200 federal, state and local law enforcement agencies in over 100 countries. In 2012, he founded Achilles Technology Solutions LLC, which, through subsidiary ATS Armor, developed a line of ballistic solutions for law enforcement and military applications. Smith holds a B.S. in ecology and evolutionary biology from the University of Arizona and an M.B.A. from Northern Arizona University.

Jim Barnes, Chief Financial Officer
Jim Barnes has served as president of Sunrise Capital Inc., a private venture capital and financial and regulatory consulting firm, since 1984. Barnes was chief financial officer of Parametric Sound Corporation (now Turtle Beach Corporation), and also served as vice president administration at Turtle Beach Corporation. Since 1999, Barnes has been manager of Syzygy Licensing LLC, a private technology invention and licensing company he owns with Elwood Norris. Barnes previously practiced as a certified public accountant and management consultant with Ernst & Ernst and Touche Ross & Co., and as a principal in J. McDonald & Co. Ltd. in Phoenix, Arizona.

Wrap Technologies Inc. (NASDAQ: WRTC), closed Wednesday's trading session at $8.59, off by 2.0525%, on 1,357,626 volume with 7,312 trades. The average volume for the last 3 months is 1,762,101 and the stock's 52-week low/high is $3.06999993/$14.3999996.

Recent News

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy (TSX.V: PQE) (OTC: PQEFF), an integrated oil company focused on the development and implementation of its proprietary oil-extraction and remediation technologies, today released a shareholder update regarding recent ‎transactions relating to the company. Among other highlights, the update discussed Petroteq’s entry into an agreement with Valkor Energy Services LLC. Under the agreement, Valkor will assume responsibility for the management and operations of Petroteq’s existing oil sands plant at Asphalt Ridge, Utah. To view the full press release, visit http://ibn.fm/KG8rt

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil sands exploration and production on mineral leases in Vernal, Utah, and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 2,500-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Clean Oil Recovery Technology (CORT) System.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ. PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy Chairman Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry.

“API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy Inc. (PQEFF), closed Wednesday's trading session at $0.0868, off by 3.5556%, on 348,227 volume with 32 trades. The average volume for the last 3 months is 867,175 and the stock's 52-week low/high is $0.017999999/$0.337599992.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has announced that it joins the lineup of presenters at this year’s LD 500 Virtual Investor Conference. The annual LD Conference spotlights some of the most prominent companies in the micro-cap world, and also includes interviews and keynotes with small-cap leaders. GNPX chairman and CEO Rodney Varner will provde a company overview as well as updates on Genprex’s lead drug candidate, GPX-001, which recently received fast track designation from the U.S. Food and Drug Administration for use in combination with AstraZeneca's Tagrisso(R) for treatment of late-stage lung cancer with EGFR mutations; the presentation will also include a summary of the company's preclinical diabetes gene-therapy candidate designed to treat, and perhaps cure, type 1 and type 2 diabetes. To view the full press release, visit http://ibn.fm/ZMAeb

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprexâ„¢ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprexâ„¢, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprexâ„¢ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprexâ„¢.

Genprex Inc. (NASDAQ: GNPX), closed Wednesday's trading session at $3.86, off by 6.3107%, on 1,294,110 volume with 4,243 trades. The average volume for the last 3 months is 1,787,604 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.